← Ablatotech Vitals
Immunology EvidenceDigest

Evaluating the clinical impact and management of immune-related adverse events from cancer immunotherapy in autoimmune patients

Immunology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
November 17, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but pose significant risks of immune-related adverse events (irAEs), particularly in patients with pre-existing autoimmune diseases. Evidence indicates that autoimmune patients receiving ICIs experience higher rates of irAEs, which may necessitate immunosuppressive management and careful balancing of cancer control with autoimmune flare risk. Current management strategies emphasize early recognition, multidisciplinary collaboration, and tailored immunomodulation to mitigate irAEs without compromising oncologic outcomes.

Clinical bottom line

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but pose significant risks of immune-related adverse events (irAEs), particularly in patients with pre-existing autoimmune diseases. Evidence indicates that autoimmune patients receiving ICIs experience higher rates of irAEs, which may necessitate immunosuppressive management and careful balancing of cancer control with autoimmune flare risk. Current management strategies emphasize early recognition, multidisciplinary collaboration, and tailored immunomodulation to mitigate irAEs without compromising oncologic outcomes.

What the evidence shows

Immune-related adverse events arise from nonspecific immune activation by ICIs, leading to inflammation in various organ systems. Autoimmune patients represent a vulnerable population, as pre-existing immune dysregulation may predispose to exacerbated irAEs (Calabrese et al., 2021). The spectrum of irAEs includes rheumatologic manifestations such as arthritis, myositis, and vasculitis, alongside more common toxicities like colitis and pneumonitis.

Recent data from Vidula et al. (2024) analyzing breast cancer patients with autoimmune diseases treated with ICIs demonstrated increased incidence and severity of irAEs compared to non-autoimmune cohorts. Notably, autoimmune flares occurred in approximately 40–50% of patients, often requiring corticosteroids or other immunosuppressants. Despite this, many patients maintained oncologic benefit, underscoring the feasibility of ICI therapy with vigilant monitoring.

Kottschade et al. (2018) provide a comprehensive framework for managing irAEs, emphasizing early identification and grading of toxicities, with corticosteroids as first-line therapy for moderate to severe events. Refractory cases may require additional immunomodulators such as TNF inhibitors or mycophenolate mofetil. Importantly, immunosuppression does not appear to significantly impair cancer outcomes when appropriately timed.

Predictive modeling efforts, though preliminary, aim to identify patients at highest risk for irAEs. Reid et al. (2022) highlight clinical and laboratory parameters that may inform risk stratification, though validated predictive tools remain lacking. Multidisciplinary care involving oncologists, rheumatologists, and other specialists is critical for optimizing management.

Caveats and uncertainty

The heterogeneity of autoimmune diseases and variability in ICI regimens complicate generalization of findings. Most data derive from retrospective cohorts or case series, limiting causal inference. Prospective trials specifically addressing autoimmune populations are scarce due to exclusion criteria in pivotal ICI studies.

The balance between controlling irAEs and preserving antitumor immunity remains delicate. High-dose or prolonged immunosuppression may theoretically reduce ICI efficacy, though current evidence suggests this risk is modest (Calabrese et al., 2021). Optimal timing, dosing, and choice of immunomodulators require further study.

Additionally, the long-term outcomes of irAEs and autoimmune flares in this context are not well characterized. Some irAEs may persist or become chronic, necessitating ongoing management. The impact of emerging ICI combinations and novel immunotherapies on irAE risk in autoimmune patients is an evolving area.

How this may change practice

Clinicians should carefully assess autoimmune disease activity and history prior to initiating ICIs, engaging rheumatology consultation early. Patients should be counseled regarding increased irAE risk and the potential need for immunosuppressive therapy.

Routine monitoring for irAEs, including subclinical autoimmune activity, is essential. Prompt intervention with corticosteroids or steroid-sparing agents can mitigate morbidity and allow continuation of cancer immunotherapy when feasible.

Development and integration of predictive biomarkers may enable personalized risk stratification and preemptive management strategies. Multidisciplinary collaboration is paramount to balance effective cancer treatment with autoimmune disease control.

As evidence evolves, clinicians should remain updated on emerging guidelines and therapeutic options to optimize outcomes for this complex patient population.


References

  1. Kottschade L, et al. Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitor Therapy. The Basics of Cancer Immunotherapy. 2018. DOI:10.1007/978-3-319-70622-1_9
  2. Calabrese LH, et al. Immunopathogenesis of Immune-Related Adverse Events from Cancer Immunotherapy. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy. 2021. DOI:10.1007/978-3-030-56824-5_3
  3. Reid PD, et al. Immune-Related Adverse Events from Cancer Immunotherapy. Clinical Innovation in Rheumatology. 2022. DOI:10.1201/9781003207160-12
  4. Vidula N, et al. Immune related adverse events in patients with breast cancer and autoimmune disease treated with immunotherapy. Journal of Clinical Oncology. 2024. DOI:10.1200/jco.2024.42.16_suppl.1103

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team